Navigation Links
Cancer protein's surprising role as memory regulator
Date:9/22/2011

BOSTON--Scientists at Dana-Farber Cancer Institute and Harvard Medical School have found that a common cancer protein leads a second, totally different life in normal adult brain cells: It helps regulates memory formation and may be implicated in Alzheimer's disease.

Cyclin E is a well-known culprit that drives many types of solid tumors and blood cancers. The report, published online in Developmental Cell, is the first revelation that cyclin E has a crucial role in the formation of nerve connections, or synapses, in the brain. Synapses are tiny connections between brain cells where memories are stored.

"This protein has a double life," said Peter Sicinski, PhD, a cancer biologist at Dana-Farber and senior author of the publication. "It is overexpressed in many different cancers, but it also is expressed in high levels in the human brain. We have found that cyclin E is needed for memory formation and is a very important player."

The researchers found potential evidence linking cyclin E to Alzheimer's disease, because it binds to an enzyme called Cdk5 that is involved in memory.

"There is good evidence that hyperactivity of Cdk5 contributes to Alzheimer's disease and inhibiting this enzyme can ameliorate symptoms in animals," said Sicinski, who is also a professor of Genetics at Harvard Medical School. "Manipulating cyclin E levels might be another way to accomplish this."

The scientists didn't test cyclin E in Alzheimer's mice, but they did show that when cyclin E binds to Cdk5 molecules, it locks them away in an unusable form. Moreover, when the researchers reduced cyclin E levels in mouse brain cells, fewer nerve connections formed and the animals' memories suffered.

Cyclins are a family of related proteins found in dividing cells. They serve as biological switches, controlling a cell's progression from one phase of its life cycle to the next. The actual signals to exit one phase and enter the next are issued by enzymes called cyclin-dependent kinases, or Cdks, that bind to cyclins.

Many types of cancer cells, including breast, ovarian, colon, and blood cancers, are driven by the overexpression of cyclin E, which acts like a car's accelerator pressed to the floor, speeding the cells through their growth-and-division cycle and allowing tumors to form and spread.

Though cyclin E is mainly found in dividing cells, researchers discover about a decade ago that cyclin E is also plentiful in adult, differentiated brain cells. But what it was doing there, no one knew.

In the current Developmental Cell paper, Junko Odajima, PhD, a postdoctoral fellow in the Sicinski laboratory and the paper's co-lead author (with Zachary P. Wills, PhD, from Harvard Medical School), showed that cyclin E in the brain attaches itself to the Cdk5 enzyme. When cyclin E molecules bind to and inactive Cdk5, synapses formation is increased, and, presumably, memory function improves.

Odajima tested this idea using a standard memory and learning test in which mice swimming in water must find a submerged platform to rest on, and remember its location in subsequent trials. The researchers then move the platform, requiring the animals to "forget" its previous location and learn and remember the new one.

As their hypothesis had suggested, mice deficient in cyclin E performed worse than rodents who had a normal amount of cyclin E. This contrast highlighted the importance of cyclin E for learning and memory.

Whether cyclin E levels rise and fall in the mouse brain during learning tasks is a topic of further research, said the scientists, who also plan to determine whether abnormal cyclin E levels can be linked to neurological diseases and learning disorders.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert  

Related biology news :

1. UCLA researchers develop system that finds prostate cancer spread earlier than conventional imaging
2. Another step toward resisting breast cancer
3. SuviCa Inc. of Boulder to commercialize CU-Boulder cancer screening technology
4. Soy peptide + chemo drug block colon cancers spread to liver
5. Oncologists recognized by ESMO for outstanding contributions to cancer research and treatment
6. Purdue technology used in first fluorescence-guided ovarian cancer surgery
7. AACR to host conference on the science of cancer health disparities
8. MU researchers unveil new method for detecting lung cancer in Nature article
9. Protein found in heart may be target for colon cancer therapies
10. Plant compound reduces breast cancer mortality
11. Primary component in turmeric kicks off cancer-killing mechanisms in human saliva
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer protein's surprising role as memory regulator
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: